2018-08-222018-08-222012FERREIRA, Anderson J.; MURÇA, Tatiane M.; FRAGA-SILVA, Rodrigo A.; CASTRO, Carlos Henrique; RAIZADA, Mohan K.; SANTOS, Robson A. S. New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis. International Journal of Hypertension, London, v. 2012, p. 1-13, 2012.2090-0384e- 2090-0392http://repositorio.bc.ufg.br/handle/ri/15692Angiotensin (Ang)-(1–7) is now recognized as a biologically active component of the renin-angiotensin system (RAS). The discovery of the angiotensin-converting enzyme homologue ACE2 revealed important metabolic pathways involved in the Ang- (1–7) synthesis. This enzyme can form Ang-(1–7) from Ang II or less efficiently through hydrolysis of Ang I to Ang-(1–9) with subsequent Ang-(1–7) formation. Additionally, it is well established that the G protein-coupled receptor Mas is a functional ligand site for Ang-(1–7). The axis formed by ACE2/Ang-(1–7)/Mas represents an endogenous counter regulatory pathway within the RAS whose actions are opposite to the vasoconstrictor/proliferative arm of the RAS constituted by ACE/Ang II/AT 1 receptor. In this review we will discuss recent findings concerning the biological role of the ACE2/Ang-(1–7)/Mas arm in the cardiovascular and pulmonary system. Also, we will highlight the initiatives to develop potential therapeutic strategies based on this axis.engAcesso AbertoArtigo10.1155/2012/147825